Physician profile
Emmanuel Lee
NPI 1821163122
$4,041.90
in general payments reported to CMS, 2019-2025
36 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2023: $648 · 2024: $1,929 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,913.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $540.79 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $455.55 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $312.63 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $304.91 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $302.22 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $281.38 | 2024-2025 | Gemtesa |
| Abbvie INC. | $232.26 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.58 | 2023-2025 | Jardiance |
| Pfizer INC. | $152.90 | 2019-2025 | |
| Shield Therapeutics INC | $133.37 | 2023-2025 | Accrufer |
| Glaxosmithkline, LLC. | $129.82 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $91.95 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Dexcom, INC. | $90.35 | 2024-2025 | Dexcom G6 Transmitter |
| Corium, LLC | $81.14 | 2025 | Azstarys |
| Exact Sciences Corporation | $79.67 | 2025 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $75.34 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $46.11 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $44.25 | 2024 | |
| Viiv Healthcare Company | $43.55 | 2024 | Apretude |
| Otsuka America Pharmaceutical, INC. | $43.18 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $37.73 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $37.20 | 2025 | Zoryve |
| Shire North American Group INC | $33.87 | 2019 | |
| Bausch Health US, LLC | $33.73 | 2023-2024 | Aplenzin |
| Genentech USA, INC. | $31.60 | 2019 | |
| Supernus Pharmaceuticals, INC. | $30.78 | 2023 | Qelbree |
| Alvogen INC | $25.51 | 2024 | Teriparatide |
| Collegium Pharmaceutical, INC. | $24.51 | 2025 | Jornay Pm |
| Alk-Abello, INC | $24.36 | 2024 | Grastek, Ragwitek, Odactra |
| Phathom Pharmaceuticals, INC. | $21.65 | 2024 | Voquezna |
| Astellas Pharma US INC | $20.33 | 2023 | Veozah |
| Medtronic, INC. | $19.23 | 2024 | Intellis Adaptivestim |
| Inspire Medical Systems, INC. | $19.22 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $18.63 | 2024 | Trintellix |
| Tms Neurohealth Centers INC. | $15.38 | 2025 | Tms Neurohealth Centers INC. |
| Allergan, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.